Medicaid cracks down on hidden drug markups by PBMs and managed care

What it does

This bill requires Medicaid to conduct monthly surveys of pharmacy drug acquisition costs nationwide and mandates that pharmacy benefit managers (PBMs) and managed care entities use transparent "pass-through" pricing models where they charge states only the actual drug cost plus a fair dispensing fee, with no hidden markups or spread pricing allowed. Pharmacies that refuse to report pricing data face civil penalties up to $100,000 per violation, and the bill creates new oversight mechanisms to detect abusive pricing practices.

Why we flagged it

The bill's core mechanism is a regulatory mandate requiring transparent pass-through pricing for prescription drugs in Medicaid and establishing a national pharmacy acquisition cost survey. It is fundamentally a price-control and transparency measure targeting pharmacy benefit managers and managed care entities, not a commemorative or appropriations bill.

What the text implies

• The 18-month delayed application to non-retail pharmacies (mail-order, specialty) may allow those entities to adjust business models before compliance, potentially creating a window for cost-shifting or restructuring.
• The bill exempts implementation from the Administrative Procedure Act and Paperwork Reduction Act, allowing HHS to issue guidance and collect data without standard notice-and-comment rulemaking, which may reduce transparency in how rules are written.

The full analysis lists 5 implications of this text.

Who stands to gain

Medicaid state programs (reduced drug costs and hidden markups); Medicaid beneficiaries (lower out-of-pocket costs for prescriptions); Independent and retail community pharmacies (reduced competition from PBM-owned entities, more trans